EUVIMEDEUVIMED entdecken
Crossref

Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases

Do H Kim, L Jeffrey Medeiros, Jie Xu, Guilin Tang, Lianqun Qiu, Sa A Wang, Chi Y Ok, Wei Wang, C Cameron Yin, M James You, Sofia Garces, Pei Lin und 1 weitere

Modern Pathology · 2025-05 · 38 (5) · 100710

DOI: 10.1016/j.modpat.2025.100710 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2025-05. Verfasst von Do H Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-bcl-6, Proto-Oncogene Proteins c-myc, Gene Rearrangement. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Classification of cases of diffuse large B-cell lymphoma (DLBCL)/high-grade B-cell lymphoma (HGBL) with MYC and BCL6 rearrangements, referred to here as BCL6 double-hit lymphoma (DHL), is controversial. We assessed 60 cases of BCL6-DHL and compared this cohort to 224 cases of DHL with MYC and BCL2 rearrangements (BCL2-DHL) and 217 cases of DLBCL not otherwise specified. Compared with the DLBCL cohort, patients with BCL6-DHL had more aggressive clinical features such as frequent extranodal involvement, high-stage disease, a high International Prognostic Index score, and an elevated serum lactate dehydrogenase level (P < .01 for all). Compared with the BCL2-DHL cohort, patients with BCL6-DHL had similarly aggressive clinical features but a lower frequency of germinal center B-cell (GCB) immunophenotype and MYC and BCL2 double expression. Patients with BCL6-DHL showed overall survival (OS) intermediate between patients with DLBCL and BCL2-DHL. Following induction with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, patients with BCL6-DHL demonstrated poor OS similar to patients with BCL2-DHL and worse OS than that of patients with DLBCL (P = .024). However, among patients who received rituximab, etoposide phosphate, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH), there was no significant difference in OS among the 3 groups (P = .146). Gene expression profiling showed that 60% of BCL6-DHL cases had a double-hit (DH)-like signature compared with 10% of DLBCL-GCB and 93% of BCL2-DHL cases. The DH-like signature in BCL6-DHL cases was associated with a GCB immunophenotype. Based on these data, we suggest that BCL6-DHL cases are clinically more aggressive than DLBCL and patients may benefit from a more aggressive therapy than R-CHOP. The data also suggest that BCL6-DHL, as currently defined, is heterogeneous and that neoplasms with a GCB immunophenotype are more likely to have a DH-like signature and behave more aggressively. Last, we suggest that BCL6-DHL cases deserve to be recognized separately in a lymphoma classification to facilitate further understanding of these neoplasms and for optimal patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycGene RearrangementBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideProto-Oncogene Proteins c-bcl-2PrednisoneVincristineDoxorubicinYoung Adult

Stichwörter der Autor:innen

BCL6MYCR-EPOCHdiffuse large B-cell lymphomadouble-hit lymphomahigh-grade B-cell lymphoma

Substanzen

Proto-Oncogene Proteins c-bcl-6BCL6 protein, humanProto-Oncogene Proteins c-mycMYC protein, humanCyclophosphamideProto-Oncogene Proteins c-bcl-2Biomarkers, TumorPrednisoneVincristineDoxorubicin

Autor:innen und Institutionen

  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: SLi6@mdanderson.org.

Zitieren

APA

Kim, D. H., Medeiros, L. J., Xu, J., Tang, G., Qiu, L., Wang, S. A., Ok, C. Y., Wang, W., Yin, C. C., You, M. J., Garces, S., Lin, P., & Li, S. (2025). Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases. Modern Pathology, 38(5), 100710. https://doi.org/10.1016/j.modpat.2025.100710

Vancouver

Kim DH, Medeiros LJ, Xu J, Tang G, Qiu L, Wang SA, et al. Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases. Modern Pathology. 2025;38(5):100710. doi:10.1016/j.modpat.2025.100710

BibTeX
@article{Kim2025,
  author = {Kim, Do H and Medeiros, L Jeffrey and Xu, Jie and Tang, Guilin and Qiu, Lianqun and Wang, Sa A and Ok, Chi Y and Wang, Wei and Yin, C Cameron and You, M James and Garces, Sofia and Lin, Pei and Li, Shaoying},
  title = {Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases},
  journal = {Modern Pathology},
  year = {2025},
  volume = {38},
  number = {5},
  pages = {100710},
  doi = {10.1016/j.modpat.2025.100710}
}
Kostenlos starten →